Ingemar Kihlström, born 1952

Chairman of the Board since 2006. Board member since 2003.

Associate Professor at Uppsala University. Ingemar Kihlström has worked with preclinical, clinical research and business development at Astra AB and Pharmacia AB for more than fifteen years. He has more than 10 years’ experience from the financial sector as an pharmaceutical analyst at companies such as Aros and ABG Sundal Collier. He is now an independent advisor to the biotech/medtech/pharmaceutical sector.

Other assignments

Chairman of the board of Recopharma AB, Creative Antibiotics AB and Hammercap AB, deputy chairman of the board of DiaGenic ASA, director of Health Invest Partners AB, Kezzler AS, Miris AB, Medivir AB, Oxypharma AB and Respiratorius AB. Independent of the Company, management team and major shareholders in the Company.

Holding in Artimplant

149 300 Series B stock units. No options in Artimplant.

Anna Malm Bernsten, born 1961

Board member since 2007. Deputy Board member in 2006.

MScEng. She runs her own consultancy company inmanagement and business development. Apart from experience in leading positions at GE Healthcare LifeSciences, Pharmacia, Assa Abloy, Medivir and Baxter Medical, she has also been president and CEO ofCarmeda AB. Director of Fagerhult AB and Medivir AB. 

Other assignments

Holding in Artimplant

No shares or options in Artimplant.

Wenche Rolfsen Sandsborg,  born 1952

Board member since 2007.

PhD in pharmacy, Associate Professor and Adjunct Professor at Uppsala University. Wenche Rolfsen Sandsborg has 16 years’ experience in leading positions within preclinical research and development at Pharmacia. She was responsible for the early clinical organization for Quintiles Europe and was president of Quintiles Scandinavia for a total of 11 years.

Other assignments

Chairman of the board of Aprea AB and Denator AB. Director of Biovitrum AB, Industrifonden AB, TFS AB and Aker Biomarine AS. Independent of the Company, management team and major stockholders in the Company.

Holding in Artimplant

20 000 Series B stock units. No options in Artimplant.

Mats Lindquist,  born 1951

Board member since 2008.

Degrees from Uppsala University in psychology and economics. Employed by the Chamber of Commerce in the County of Uppsala. Formerly Vice President, Corporate Development for the contract research company Quintiles Transnational Corp. During the period 1998-2005, Mats Lindquist was President of Quintiles AB’s operations in the Nordic region and the Baltic countries. Prior to this he held a number of different managerial positions within the global and local pharmaceutical industry.

Other assignments

Independent of the Company, management team and major stockholders in the Company.

Holding in Artimplant

30 000 Series B stock units. No options in Artimplant.

Håkan Johansson, born 1955

Board member since 2010

MSc in business administration. Independent advisor and Board member. Advisor to the private equity funds managed by EQT. Former Senior Partner at EQT, Division manager for Electrolux Industrial Laundry Division and CEO for Electrolux Wascator AB, responsible for mergers & acquisitions at Electrolux, Vice President & Treasurer at Volvo Group as well as a number of positions within finance and investor relations at Volvo. 

Other assignments

Chairman of the Board in Priority Aero Maintenance AB, Board member in Stena Adactum and Volvo Technology Transfer. Independent of the Company, management team and major stockholders in the Company.

Holding in Artimplant

Auditors

Ernst Young AB

Responsible partner

Björn Grundvall, born 1955. Auditor since 2010.

Authorized Public Accountant